Steatotic liver disease is a common condition where extra fat builds up in the liver and can inflame or scar it over time. Many people with steatotic liver disease have no symptoms at first, but some feel tired or notice right‑upper belly discomfort. It tends to develop slowly and can progress, but most people live a normal lifespan, especially with early care. Adults with higher weight, type 2 diabetes, high cholesterol, or heavy alcohol use are most affected, and children can be affected too. Treatment for steatotic liver disease focuses on weight loss, regular activity, healthy eating, managing diabetes and cholesterol, limiting or avoiding alcohol, and medicines or procedures when liver damage is advanced.
Overview
Steatotic liver diseaseSymptoms
Steatotic liver disease often causes no symptoms. Some people notice tiredness, vague fullness or discomfort under the right ribs. Advanced disease can bring jaundice, swollen belly or legs, easy bruising, and itching.
Outlook and prognosis
Most people with steatotic liver disease do well, especially when weight, blood sugar, and cholesterol are managed. Liver inflammation and scarring can develop slowly, so steady follow-up matters. With lifestyle changes and targeted care, long-term liver health often stabilizes.
Causes and risk factors
Steatotic liver disease arises from excess liver fat, usually linked to insulin resistance and metabolic syndrome. Risk factors include overweight, type 2 diabetes, high triglycerides, hypertension, sedentary lifestyle, sugary drinks, sleep apnea, and inherited genetic variants.
Genetic influences
Genetics play a meaningful role in steatotic liver disease risk and progression, but lifestyle and metabolic health remain major drivers. Variants in genes like PNPLA3, TM6SF2, and MBOAT7 can raise susceptibility and severity. Family history can guide screening.
Diagnosis
The diagnosis of Steatotic liver disease uses history, exam, and blood tests, while ruling out alcohol and other causes. Ultrasound or FibroScan check liver fat and stiffness; MRI may help. Biopsy is considered when fibrosis stage or diagnosis remains uncertain.
Treatment and drugs
Treatment for steatotic liver disease focuses on easing liver fat and inflammation, protecting the liver, and lowering heart and diabetes risks. Plans often include gradual weight loss, tailored nutrition, regular activity, limiting alcohol, and managing cholesterol, blood pressure, and blood sugar. Some may benefit from vitamin E, diabetes medicines that reduce liver fat, or surgery for severe obesity, alongside regular monitoring.
Symptoms
Many people with steatotic liver disease feel well at first, with nothing obvious to point to the liver. Early symptoms of steatotic liver disease can be easy to miss, like low energy or a dull ache under the right ribs. As fat and inflammation build over time, some develop signs of more serious liver stress. Symptoms vary from person to person and can change over time.
Many people notice nothing for years even as fat builds up in the liver. Steatotic liver disease is often found on routine blood work or an ultrasound done for another reason.
Persistent tiredness or low stamina is common. Day to day, it can feel like errands or workouts take more effort than they used to.
A dull ache or sense of heaviness under the right ribs can come and go. It’s usually mild but nagging, especially after meals.
Feeling bloated or full quickly can happen. In daily routines, this might show up as small but noticeable changes like stopping meals early.
How people usually first notice Steatotic liver disease?
Many people first notice steatotic liver disease when a routine blood test shows mildly elevated liver enzymes, even though they feel fine. Others learn about it after an ultrasound for belly discomfort, fatigue, or a feeling of fullness on the right side reveals extra fat in the liver—these are common first signs of steatotic liver disease. Sometimes it’s flagged during checkups for risk factors like higher body weight, type 2 diabetes, high cholesterol, or high blood pressure, which often travel together with this condition.
Types of Steatotic liver disease
Steatotic liver disease has a few well-defined types that reflect what’s driving fat buildup in the liver and how inflamed or scarred it becomes over time. This helps explain why symptoms can range from none at all to fatigue or discomfort under the right ribs. Clinicians often describe them in these categories: simple fat accumulation without inflammation, inflammation with liver-cell injury, and alcohol-related forms, with special cases during pregnancy or from certain medicines. Understanding the main types of steatotic liver disease can make it easier to discuss early symptoms of steatotic liver disease with your care team.
MASLD (metabolic)
Fat builds up in the liver in the setting of metabolic risk, such as higher weight, type 2 diabetes, or high triglycerides. Many have no symptoms, while some notice tiredness or a dull ache in the upper right belly. Liver tests may be slightly raised, and imaging often shows fat.
MASH (inflamed MASLD)
This is MASLD with ongoing inflammation and liver-cell injury. People may feel more fatigue or abdominal discomfort, and doctors may see higher liver enzymes. Without treatment, it can progress to scarring.
Alcohol-related fatty
Fatty liver driven by ongoing alcohol exposure. Symptoms may be absent early, but can include fatigue or decreased appetite as inflammation develops. Cutting back or stopping alcohol can improve the liver.
Drug-induced fatty
Certain medicines can trigger liver fat buildup or inflammation. Symptoms may include nausea, tiredness, or upper belly discomfort, and changes often improve when the medication is adjusted. Your clinician will balance benefits and risks before switching therapies.
Lean MASLD
Fatty liver in people with a normal body weight. Symptoms are similar to other types, but risk factors may include subtle metabolic issues or genetic predisposition. It still warrants lifestyle attention and monitoring.
Advanced fibrosis/cirrhosis
Long-standing inflamed types can lead to stiff, scarred liver tissue. People may notice swelling in the legs or belly, itchy skin, or easy bruising, and doctors may find a shrunken, nodular liver. Early detection aims to slow or prevent further scarring.
Pregnancy-related (AFLP)
A rare condition in late pregnancy where fat overwhelms the liver. People may feel sudden nausea, belly pain, and weakness, and doctors treat it urgently to protect the parent and baby. Recovery usually follows delivery with careful monitoring.
What genetics can tell you about symptoms
Some people with steatotic liver disease develop faster scarring and earlier inflammation when they carry PNPLA3 (I148M) or TM6SF2 (E167K) variants, which make liver cells store fat more easily. Others with protective variants in HSD17B13 may have fatty liver but fewer symptoms.
Causes and risk factors
Steatotic liver disease often starts when too much fat builds up in the liver.
It is closely linked to insulin resistance, type 2 diabetes, and extra weight around the waist.
Unhealthy diet, low physical activity, and regular alcohol use can raise risk for steatotic liver disease.
Family history and certain gene changes can increase risk, and some medicines or rapid weight loss can also contribute.
Some risks are modifiable (things you can change), others are non-modifiable (things you can’t).
Environmental and biological risk factors
Steatotic liver disease develops when extra fat builds up in the liver over time. Doctors often group risks into internal (biological) and external (environmental). If you're concerned about early symptoms of steatotic liver disease, it can help to understand which body-based changes and outside exposures may raise risk. Below are key environmental and biological factors linked to this condition.
When the body resists insulin, the liver absorbs more fatty acids and makes extra fat. This state is common in prediabetes and type 2 diabetes and is a major driver of steatotic liver disease.
Carrying more fat, especially around the waist, increases fatty acid flow to the liver. This imbalance raises the chance of steatotic liver disease.
Elevated blood fats push more fat toward the liver and reduce fat export from liver cells. This combination can lead to steatotic liver disease over time.
An underactive thyroid slows the body’s energy use and fat processing. That slowdown can promote fat build-up in the liver.
Genetic risk factors
Genes play a meaningful role in who develops fat buildup in the liver and who progresses to scarring or liver cancer. Several inherited changes raise or lower the chance of steatotic liver disease, and different ancestries carry different patterns. Carrying a genetic change doesn’t guarantee the condition will appear, but it can shift risk and help explain why early symptoms of steatotic liver disease are often silent. Understanding genetic risk factors for steatotic liver disease may guide testing and closer follow-up in some families.
PNPLA3 variant: A common change in the PNPLA3 gene (often called I148M) strongly raises the chance of fat buildup in the liver and scarring. People with two copies have the highest risk of steatotic liver disease and related complications. This variant helps explain why risk can cluster in some families.
TM6SF2 variant: The E167K change in TM6SF2 can reduce the liver’s ability to export fat, so more fat stays in liver cells. This increases the chance of steatotic liver disease and faster progression to inflammation and fibrosis.
GCKR variant: Certain forms of GCKR push the liver to turn more sugar into fat. That extra fat can drive steatotic liver disease and raise liver enzyme levels on blood tests.
MBOAT7 variant: A risk variant near MBOAT7 is linked to higher liver fat and more inflammation. People carrying it may have a greater chance of steatohepatitis and fibrosis.
HSD17B13 protective: Loss-of-function changes in HSD17B13 tend to protect against liver inflammation and scarring. People with these variants may have lower odds of severe steatotic liver disease even when other genetic risks are present.
MARC1 protective: Certain MARC1 variants are associated with lower liver fat and healthier liver enzyme levels. They appear to reduce the risk of steatotic liver disease complications.
Rare lipid disorders: Inherited conditions such as familial hypobetalipoproteinemia (APOB) or abetalipoproteinemia (MTTP) can cause marked liver fat from childhood. These rare syndromes often lead to steatotic liver disease and need specialist care.
Alpha-1 antitrypsin: SERPINA1 gene changes (like ZZ or SZ types) can cause ongoing liver injury and cirrhosis. Some people with these variants also develop liver fat, adding to the burden of steatotic liver disease.
HFE iron overload: Variants such as C282Y or H63D can lead to hereditary hemochromatosis with iron buildup in the liver. Extra iron can worsen scarring in people with steatotic liver disease.
Lipodystrophy genes: Genetic forms of partial or generalized lipodystrophy (for example, LMNA or PPARG) redistribute body fat and create severe insulin resistance. The liver then stores excess fat, often causing early and severe steatotic liver disease.
Family history: Having close relatives with fatty liver signals inherited susceptibility. Twin and family studies show that steatotic liver disease often runs in families.
Ancestry background: The frequency of key variants differs by ancestry, which changes average risk. For example, the PNPLA3 risk variant is more common in many Hispanic/Latino groups, partly explaining higher rates of steatotic liver disease.
Lifestyle risk factors
Steatotic liver disease is strongly shaped by everyday habits that influence insulin resistance, liver fat production, and inflammation. Understanding the lifestyle risk factors for Steatotic liver disease can guide practical changes to slow or reverse fat buildup and protect liver function. Diet quality, activity patterns, sleep, and alcohol use each play a direct role in how the disease progresses.
Regularly eating more calories than you burn drives fat storage in the liver. Sustained energy surplus worsens insulin resistance and raises the risk of inflammation and fibrosis.
Fructose-rich sodas and juices accelerate de novo lipogenesis in the liver. Frequent intake is linked to higher liver fat and worse metabolic markers.
White bread, pastries, and sweets spike blood sugar and insulin. Repeated surges promote liver fat deposition and worsen steatosis.
Diets high in saturated and trans fats increase hepatic fat and inflammation. Replacing them with unsaturated fats can reduce liver fat over time.
Risk prevention
Steatotic liver disease often develops quietly, but there’s a lot you can do to lower risk and protect your liver over time. Early symptoms of steatotic liver disease are uncommon, so focusing on everyday prevention pays off. Prevention can mean both medical steps, like vaccines, and lifestyle steps, like exercise. Work with your care team to tailor these to your health, medicines, and daily life.
Losing 7–10% of your body weight can reduce liver fat and inflammation. For someone at 100 kg (220 lb), that’s about 7–10 kg (15–22 lb). Aim for gradual, steady changes.
Target at least 150–300 minutes of moderate exercise weekly or 75–150 minutes of vigorous exercise. Include muscle-strengthening on 2 or more days. Even brisk walks and short movement breaks help.
Choose a Mediterranean-style pattern rich in vegetables, legumes, whole grains, fish, nuts, and olive oil. Cut back on sugary drinks, refined carbs, and high-fructose snacks to lower liver fat. Portion awareness matters as much as food type.
Alcohol can add stress to a fatty liver, so minimizing or avoiding it lowers risk. If you drink, stay within low-risk limits—up to 1 drink a day for women and up to 2 for men (about 14–28 g alcohol/day). Skip drinking on days you take acetaminophen/paracetamol.
Transmission
Steatotic liver disease is not contagious; you can’t catch it from someone or spread it through casual contact, food, sex, coughing, or blood (including shared needles). Instead of an infection, it develops over time from metabolic health factors, and depending on the subtype, alcohol use may play a role. It can run in families, but there is no simple genetic transmission of Steatotic liver disease—some gene variants can raise risk, yet lifestyle and overall health remain the main drivers. If you’re wondering how Steatotic liver disease is inherited, it’s best viewed as a mix of shared genes and environment rather than something passed directly from one person to another.
When to test your genes
Steatotic liver disease is usually diagnosed by labs and imaging, but genetic testing may help if you have fatty liver at a young age, severe disease out of proportion to lifestyle, or a strong family history. Testing can also guide care if you’re uncertain about risks despite healthy habits. Ask about panels that include PNPLA3, TM6SF2, and related variants to personalize monitoring and prevention.
Diagnosis
Steatotic liver disease is often found when everyday energy dips, the waistline increases, or routine bloodwork shows slightly abnormal liver numbers. Doctors usually begin by asking about alcohol use, weight changes, medicines, and family history, then match that with simple tests. The diagnosis of Steatotic liver disease typically combines your health history, blood tests, and imaging to confirm fat in the liver and check for scarring. Sometimes extra testing is needed to look for inflammation or to rule out other liver conditions.
Your provider asks about alcohol use, diet, weight, diabetes, and medicines, and checks your abdomen and skin. These details help tell whether fat buildup is likely and whether there are signs of scarring.
Basic panels look at liver enzymes, cholesterol, and blood sugar. Results can suggest liver stress and flag related conditions such as prediabetes or metabolic syndrome.
Additional labs check for viral hepatitis, iron overload, autoimmune liver disease, and medication effects. This helps confirm fat-related liver disease and excludes other causes that can look similar.
An abdominal ultrasound can show a “bright” liver that suggests fat accumulation. It’s painless, widely available, and often the first imaging test used.
Stages of Steatotic liver disease
Steatotic liver disease often advances quietly, so everyday life may feel normal until the liver becomes more stressed. Early symptoms of steatotic liver disease are often absent, and changes are usually picked up by blood tests or scans. Different tests may be suggested to help estimate how much fat, inflammation, and scarring are present, and sometimes a liver biopsy is needed for clarity. Staging guides follow-up and treatment to lower long‑term risk.
Simple fatty liver
Fat builds up in the liver, but there is little to no irritation or damage. Most people feel well and routine blood work or an ultrasound may be the first hint of steatotic liver disease.
Inflamed fatty liver
Fat plus irritation (often called steatohepatitis) starts to injure liver cells. You may still feel fine, though some notice fatigue or discomfort under the right ribs.
Early fibrosis
The liver lays down thin bands of scar tissue while trying to heal. Noninvasive tests that measure liver stiffness (like elastography) help estimate this stage.
Advanced fibrosis
Scarring becomes broader and more linked across the liver. Blood tests and elastography usually show higher stiffness, and doctors may discuss closer monitoring for steatotic liver disease.
Cirrhosis, compensated
Heavy scarring reshapes the liver, but it still keeps up with most tasks. People may have few or no symptoms, and regular checks look for complications and liver cancer risk.
Cirrhosis, decompensated
The liver can no longer keep up, and problems like belly fluid, swelling, confusion, or yellowing of the eyes/skin can appear. Hospital care and specialist treatment are often needed.
Outlook and prognosis
Looking at the long-term picture can be helpful. For many people with steatotic liver disease, the course is slow and measured, especially when weight, blood sugar, and blood pressure are well managed. Many people ask, “What does this mean for my future?”, and the honest answer is that most will never develop advanced liver damage, but a smaller group may progress to liver inflammation, scarring (fibrosis), and, over years, cirrhosis. The biggest drivers of progression are ongoing metabolic risks—type 2 diabetes, central weight gain, high triglycerides—along with alcohol use and certain medications.
Doctors call this the prognosis—a medical word for likely outcomes. Early symptoms of steatotic liver disease are often subtle or absent, so routine labs and imaging carry a lot of weight in spotting trouble early. If inflammation and scarring take hold, risks can include liver-related complications such as fluid build-up, bleeding, or liver cancer; these remain uncommon in those without significant fibrosis. Overall life expectancy is close to average for people without scarring, but once cirrhosis develops, the chance of liver-related illness and death rises.
The outlook is not the same for everyone, but people with diabetes, older age, or more severe fibrosis tend to face higher risks over time. On the flip side, sustained weight loss of 7–10%, regular physical activity, Mediterranean-style eating, and control of blood sugar and lipids can slow or even partially reverse early scarring. Not everyone with the same gene change will have the same outlook, and genetic testing can sometimes provide more insight into prognosis when there’s a strong family history or unusually rapid progression. Keep regular appointments—small adjustments can improve long-term health, and ask about noninvasive fibrosis scores or scans to track changes without a biopsy.
Long-term effects
Steatotic liver disease can be quiet for years, then lead to liver scarring and problems beyond the liver. Long-term effects vary widely, and not everyone follows the same path. Some people remain stable for decades, while others develop inflammation, scarring, or complications. Thinking about the long-term effects helps you and your care team plan follow-up and decide when to act early.
Many people have no warning signs for years. Early symptoms of steatotic liver disease are often absent or vague, which can delay diagnosis. Routine blood tests or imaging may be the first clue.
Ongoing irritation of the liver can develop, sometimes called steatohepatitis. This can cause fatigue or discomfort on the right side under the ribs. Over time, it raises the chance of scarring.
Repeated injury can lay down scar tissue in the liver. As scarring builds, the liver stiffens and works less well. In advanced stages, cirrhosis can develop with higher risks of complications.
With cirrhosis, pressure can rise in the vein that drains the gut. This may lead to fluid buildup in the belly, swollen spleen, or enlarged veins in the esophagus that can bleed. Doctors often describe these as long-term effects or chronic outcomes.
How is it to live with Steatotic liver disease?
Living with steatotic liver disease often means paying steady attention to everyday choices—what you eat, how you move, and how you manage weight, sleep, stress, and other conditions like diabetes or high blood pressure. Many feel well for years, yet routine labs or imaging can uncover liver fat and inflammation, so regular checkups and small, consistent lifestyle changes become the backbone of care. For families and close friends, support can look like shared meals that are balanced, walking together, and encouragement during medical visits, which helps turn treatment goals into sustainable habits. With teamwork and early attention, many people keep their liver healthy and avoid complications while maintaining full, active lives.
Treatment and drugs
Treatment for steatotic liver disease focuses on reducing liver fat, calming inflammation, and preventing scarring, while also addressing conditions that travel with it, like type 2 diabetes, high cholesterol, and high blood pressure. For many people, treatment begins with small daily steps: gradual weight loss (about 7–10% of body weight), regular physical activity, and a balanced eating pattern such as a Mediterranean-style plan; even a 5% loss can improve liver enzymes and energy levels. Doctors sometimes recommend a combination of lifestyle changes and drugs, including medicines for diabetes (like GLP‑1 receptor agonists), cholesterol‑lowering statins, and blood pressure treatments, all chosen to be safe for the liver; vitamin E may be considered in select non‑diabetic adults with liver inflammation. If you drink alcohol, cutting back or stopping is important, and vaccinations for hepatitis A and B help protect the liver; your doctor may also adjust medications that can strain the liver. Keep track of how you feel, and share this with your care team, since follow‑up blood tests and, in some cases, imaging or biopsy guide whether the plan is working and if newer therapies or clinical trials are a good fit.
Non-drug treatment
Steatotic liver disease can sap energy and make everyday meals and movement feel more complicated. Non-drug treatments often lay the foundation for getting liver fat down and protecting the liver long term. Most people do best with several small changes working together, especially if weight, blood sugar, or blood pressure also need attention. Because early symptoms of steatotic liver disease are often subtle or absent, routine follow-up helps track progress.
Losing 7–10% of body weight can reduce liver fat and inflammation. Slow, steady loss—about 0.25–0.5 kg (0.5–1 lb) per week—is safest for your liver. Aim for balanced meals rather than crash diets.
A Mediterranean-style pattern—vegetables, beans, whole grains, nuts, olive oil, and fish—helps lower liver fat. Cut back on sugary drinks and refined carbs to steady blood sugar swings. Portion guidance from a dietitian can tailor this to you.
Aim for at least 150–300 minutes a week of moderate activity, like brisk walking or cycling, plus 2–3 days of resistance training. Exercise helps even without weight loss by improving how your body uses sugar and fat. Build up gradually if you’re just getting started.
Avoid alcohol if possible, as it can worsen liver fat and scarring. If you do drink, keep it very light—no more than 1 drink a day for women and 2 for men (about 14 g alcohol per US drink). Take several alcohol-free days each week.
Your genes may have an impact on how drugs work for you
Medicines for steatotic liver disease can work differently based on gene variants that affect drug processing enzymes and liver fat pathways, changing benefit and side‑effect risk. Pharmacogenetic testing and careful dose adjustment help match the right drug and dose to you.
Pharmacological treatments
Medicines for steatotic liver disease focus on reducing liver fat, calming inflammation, slowing scarring, and lowering heart risk. Because early symptoms of steatotic liver disease can be hard to notice, treatment choices are guided by blood tests, scans, and sometimes biopsy results. Not everyone responds to the same medication in the same way. Doctors also consider other conditions like type 2 diabetes, high cholesterol, and obesity when selecting a drug.
This newer medicine (Rezdiffra) targets liver fat and scarring in people with MASH/NASH and moderate fibrosis. It requires periodic blood tests and a review of other medicines, especially statins.
Semaglutide and liraglutide help with weight loss and can reduce liver fat and liver inflammation. They are approved for diabetes or obesity, not specifically for steatotic liver disease.
This GIP/GLP-1 medicine leads to substantial weight loss and lowers liver fat in many with diabetes or obesity. It is not yet approved specifically to treat liver scarring.
This diabetes drug can improve liver inflammation and scarring in MASH/NASH, especially in people with type 2 diabetes. Potential side effects include weight gain, swelling, and a small increase in fracture risk.
Genetic influences
Family and twin studies show that genes influence who develops steatotic liver disease and how quickly it progresses. Genetics is only one piece of the puzzle, but it can tilt your baseline risk up or down. Common gene variants—such as changes in PNPLA3 or TM6SF2—can increase liver fat and raise the chance of inflammation and scarring, while others may be protective. Carrying these variants does not mean you will definitely develop liver disease. These differences are more frequent in some ancestries, which helps explain why risk can vary across groups even when lifestyle is similar. Most people with steatotic liver disease have several small genetic differences acting together rather than a single rare cause, and everyday factors like weight, type 2 diabetes, and alcohol still matter a great deal. This usually doesn’t change the early symptoms of steatotic liver disease, which are often subtle, but it can influence the chances of progression to fibrosis or cirrhosis.
Is Steatotic liver disease genetic?
Genetics play a meaningful role in steatotic liver disease risk and progression, but lifestyle and metabolic health remain major drivers. Variants in genes like PNPLA3, TM6SF2, and MBOAT7 can raise susceptibility and severity. Family history can guide screening.
Pharmacogenetics—how genetics influence drug effects
In steatotic liver disease, your genes can shape both how the condition progresses and how your body handles medicines used in care. Genes can influence how quickly you process some medicines, which can affect dose needs and the chance of side effects. For example, a common change in the SLCO1B1 gene raises the risk of muscle pain with simvastatin; knowing this can steer the choice toward a different statin or a lower dose while still treating cholesterol safely. Variants in PNPLA3, TM6SF2, or HSD17B13 are linked to how severe steatotic liver disease becomes, but they don’t yet change day‑to‑day treatment, where lifestyle changes and managing cholesterol, blood pressure, and blood sugar remain central. For newer options such as GLP‑1 medicines, pioglitazone, vitamin E, or resmetirom, gene‑based dosing isn’t established, though studies are ongoing. This kind of gene–drug matching is known as pharmacogenetics. If you’re weighing medications for steatotic liver disease, genetic testing may help with statin decisions today and could guide more personalized choices as evidence grows.
Interactions with other conditions
Living with steatotic liver disease alongside diabetes, high blood pressure, or high cholesterol can make day-to-day health feel more complicated; for many, this can mean juggling blood sugar, weight, and energy while watching liver numbers. Steatotic liver disease is closely tied to type 2 diabetes and obesity in a two‑way relationship—insulin resistance can drive liver fat, and a fatty, inflamed liver can make blood sugar control harder. Doctors call it a “comorbidity” when two conditions occur together, and in this case the most important partner is often heart disease; people with steatotic liver disease have a higher risk of heart attack and stroke than of liver failure itself. Sleep apnea, chronic kidney disease, and polycystic ovary syndrome occur more often in people with steatotic liver disease and may speed up scarring in the liver if not treated. Viral hepatitis (like hepatitis B or C) and steatotic liver disease can compound each other’s effects, raising the chance of fibrosis and cirrhosis, and alcohol use adds further strain. Early symptoms of steatotic liver disease are often absent, so coordinated care that tackles blood pressure, cholesterol, diabetes, weight, and sleep apnea can lower both liver and heart risks.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described tiredness after meals, a swollen belly, or a “yellowed” look in relatives who drank little or no alcohol. Families and communities once noticed patterns of weight gain, diabetes, and sluggish digestion appearing together, long before there was a name for what we now call steatotic liver disease. Doctors noted enlarged, tender livers during exams, while early autopsies showed pale, greasy-looking tissue. These were the first clues that fat can build up inside liver cells and silently strain the organ.
First described in the medical literature as fatty change of the liver in the 1800s, steatotic liver disease was initially linked to heavy drinking because alcohol-related damage was easier to recognize. As industrialization brought shifts in diet and activity, more people developed obesity and type 2 diabetes, and similar liver changes appeared in those who rarely drank. By the late 20th century, researchers recognized nonalcoholic forms and began using terms like nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) to separate it from alcohol-related disease.
Over time, descriptions became more precise. Ultrasound made it possible to see a “bright” liver as fat accumulated, and blood tests hinted at inflammation even when people felt well. Liver biopsy studies showed a spectrum: simple fat buildup in some, inflammation and cell injury in others, and scarring that could advance to cirrhosis. This range helped explain why two people with steatotic liver disease can have very different courses—one stable for years, another progressing to fibrosis.
In recent decades, awareness has grown as steatotic liver disease became one of the most common liver conditions worldwide. The rise mirrors global trends in metabolic health, including insulin resistance, high blood pressure, and lipid changes. Clinicians also learned that genetics, ethnicity, and age can influence risk and severity, and that children and teens can be affected, not just adults. As understanding improved, medical groups refined terminology again to emphasize metabolic drivers and reduce confusion tied to alcohol use.
Advances in imaging and noninvasive fibrosis scores now let many people be monitored without biopsy. Studies mapping early symptoms of steatotic liver disease—often none at all—pushed for screening in those with obesity, type 2 diabetes, or polycystic ovary syndrome. At the same time, long-term research confirmed that lifestyle changes can slow or reverse fat buildup, and that treating metabolic conditions helps the liver too.
Knowing the condition’s history shows why today’s approach blends careful risk assessment, simple imaging, and attention to overall metabolic health. What began as scattered observations of a heavy, pale liver has become a clearer picture of a common, largely preventable condition—one that often improves with timely, steady changes and, when needed, targeted medical care.